Haematologica 2003 - Supplements

More documents

Recommendations

Info

tumor detectable following transplantation. Vaccine based strategies aimed at inducing a tumor-specific immune response at the time of minimal residual disease are attractive in this setting but rely on adequate immune reconstitution. When this is achieved depends on the underlying disease, conditioning, stem cell source (marrow or PBSC) and whether any manipulation of graft has been used (purging or CD 34+ selection). The aim of this study was to assess the ability of patients with plasma cell disorders to generate antibody and cellular responses to tetanus toxoid (TT) vaccination (0.5ml). Immune responses were measured pre and 1 month post-vaccination. Our cohort consisted of 15 myeloma patients at least 15 months post-ASCT, 1 patient who was 3 months post ASCT, 3 patients in plateau phase after conventional chemotherapy, 2 patients with smouldering myeloma and 8 patients with MGUS. The responses of these patients were compared with those of 15 healthy volunteers. Anti-TT antibodies were measured by ELISA and cellular responses by a lymphoproliferation assay and interferon γ elispot. Each autograft patient had received melphalan, 200mg/m2 as conditioning, followed by an unmanipulated peripheral blood stem cell transplant. The median time since transplantation was 31 months (range 15-81). Only one patient was vaccinated with TT in the post-transplant period prior to this study. RESULTS: Similar to the fifteen healthy volunteers, transplant recipients who were at least 15 months post-ASCT, boosted their TT-antibodies post-vaccination. This included three who initially had non-protective levels (3) pre-vaccination in 5 /15 myeloma patients who were at least 15 months post-transplant. Each of these 5 raised their SI post-vaccination. Overall, in this transplant group the assay was positive in 12/15 post-vaccination. Three of the fifteen were found to be negative pre- and post-vaccination. The elispot assay was positive in 1/15 of these patients prior to vaccination and in 6/15 post-vaccination. One patient had a positive elispot but a negative lymphoproliferative response post-vaccination. The lymphoproliferative assay was negative both pre and postvaccination in the patient who was only 3 months post-ASCT. This result is consistent with published data on the lack of numerical CD4 T cell recovery at this stage post-transplantion. In the plateau group, the lymphoproliferation assay was positive in 1/3 patients pre-vaccination and positive in 3/3 postvaccination. Elispot results are available for one of this group and were positive both pre and post-vaccination. Five of the 8 MGUS patients had a positive lymphoproliferation assay pre-vaccination and all were positive post-vaccination. These results present new information on functional immune reconstitution post-ASCT in myeloma and help to determine the timing for vaccine-based immunotherapy in this setting. S272
Author Index Abe M 74 160 Abelman W 107 Abildgaard N 165 212 Abraham RS 136 Abrams J 197 Abroun S P3.6 Abungu B 115 Ackermann J 89 94 322 Adam Z P9.4 228 230 293 Adami F 57 Adamia S 32 Adams J 368 371 373 Affer M P1.1 1 2 Agarwal DP 246 Agostini C 57 Agrawal D P6.2 Aguado B 56 278 312 314 345 Aguilar TM 375 Aguilera C 85 C 106 Ahmad I 341 412 Ahmann G 136 Ahmann GJ 33 35 Ahsan G 203 Aitoro G P10.3.3 Akhtar N 267 Akiyama M 112 121 134 224 387 391 392 Akli J 213 Akpo-Avallo J 200 Akyerli CB 71 Aláez C 278 Alberti C P10.2.2 Albiero E 19 Albó C 291 Alegre A 36 56 278 294 304 312 314 345 Alegre-Amor A 326 Aleman A 306 Alexander W 214 Alexanian R P4.2 Alexanian R P11.3.1 352 Allegaert V 142 Allmer C 241 265 Almeida J 54 63 Almici C 144 Aloba C 348 Alonso A 312 Alonso ME 7 206 Alonso N 254 Alsina M P6.1 P12.2.1 284 Alves Carmo J 318 Amabile M 51 173 Amadori S 333 335 361 Amaranto P 279 Amariglio N 210 Amiot L 168 Amiot M 127 Anagnostopoulos A 306 328 331 Anagnostopoulos N 328 Anaissie E P11.3.2 188 358 Andersen NF 212 Anderson K P5.1 P10.1.4 P11.2.3 224 372 Anderson KC P12.1.1 P8.3 P12.1.3 P5.4 P6.5 91 112 116 118 121 123 134 135 146 303 386 387 389 391 392 Anderson S 226 Andjelkovich N 175 Andriani A 336 Anel A 384 Ángeles Hernández M 43 Angeles Montalbán M P7.6 Angeles Ruiz Mª 48 Angtuaco E 188 Annibali O 102 Ansell S 283 Ansell SM 295 Appelbaum F 303 Apperley J P11.1.1 261 286 298 305 Apperley JF 166 205 Arciprete F 361 Ardeshna K 172 Arendt BK P5.5 120 Armstrong A 219 Arnaudov G 393 Arnold C 207 Arnould C 22 Arnulf B 356 Arruga A 185 Arús C 191 192 Asensio A 181 Ashihara E 337 383 Asosingh K P8.1 P6.3 122 142 221 222 Åstrand-Grundström I 38 Atkins GJ 153 154 Attal M P10.1.1 P10.2.1 309 Auclair D 91 Auwerda H 177 Auwerda JJA 395 Avet-Loiseau H P7.1 P4.3 P2.4 45 Avvisati G 279 Axelsson M 132 Aymerich M 44 79 95 311 Ayuk F P11.2.4 Azaceta G 270 Azzará A 209 Baars JW P10.2.3 Babbage G 12 Baccarani M P11.1.2 P10.2.4 51 173 178 349 360 364 Bacigalupo A P11.1.1 Bacovsky J 88 90 194 195 230 293 Badea D 180 238 244 Badea M 180 238 244 Bader P 307 Badros A 269 332 Baesso I 57 Bahlis NJ 133 139 375 Bailey C 134 135 Bakaloudi V 145 Bakker F 113 130 223 Bakkus M 122 155 286 Bakkus MHC 205 Balanzategui A 7 206 208 Baldini L 5 80 163 252 Ballanti S 285 Ballerini F 257 Ballester G 302 Ballester OF 302 Ballman KV 120 Bamberg M 307 Bandini G P11.1.2 Banzo J 185 Baran W 308 Barbarano L 249 280 359 Barberá A 192 Barbolla L 410 Barbui A 252 273 Bardy P 154 Bárez A P10.1.3 86 204 Bargay J 291 Barge RMY P11.1.3 Bargou R 114 117 Bargou RC 73 111 124 382 Baris D 100 Barlogie B P1.1 P2.1 P1.2 P10.1.4 P11.2.3 P11.3.2 34 62 148 149 188 303 358 402 Barnes D 186 Barreiro E 36 Barrenetxea C 59 Barrenetxea M 326 Barth N 196 225 Bast BJEG 27 Bastard C 22 29 Basten A 64 Bataille R P3.1 P10.2.1 109 110 144 168 P4.3 127 Batchu R 75 402 Batuman O 348 Bauer F P9.4 Baulch-Brown C 126 390 Baum W 113 130 223 Bauters F 183 Baykov V 141 369 Bedi N 234 Begum G 196 225 Behrens J 243 Beitler B 105 Beksac M 71 Belch A P1.3 26 30 31 32 52 272 Belén González M 43 Belissant E 309 Bell H 371 Bell R 164 340 Bell S 198 243 Bell SE P10.1.2 Bello JL 294 Bendix K 212 Benedetti E 209 252 Benítez J 40 Benner A 41 205 Benni M P10.2.4 Bensinger W 287 Bensinger WI P11.2.1 274 Bentzen C 396 Berdel WE 129 300 327 330 Berenson JR P9.3 P12.2.4 18 220 373 374 376 401 Berenson R 70 Bergonzi C 252 Bergsagel PL P1.1 P1.2 1 2 4 320 Bermudo F 202 Bernhard A 207 Bernhart M 271 Bernuzzi P 359 Berthou C 309 Bertola A P10.3.3 252 273 324 Besalduch J 294 Bevan D 198 Biagi JJ 164 340 Biedermann R 162 Biesma DH P10.2.3 Bila J 235 323 Binotto G 57 Binz RL 34 Bird J 77 Bird JM 78 Bisping G 129 300 327 330 Bjorkstrand B 261 289 298 P11.1.1 Bladé J P11.1.1 P10.1.3 P7.6 36 44 79 95 227 259 294 297 311 312 Blázquez C 278 Bleuet Jë 213 Bloem AC 131 398 Blum R 187 Boccadoro M P10.3.3 252 273 324 Bodenizza C 344 Boersma-Vreugdenhil GR 27 Bogen B P13.5 Boiron J 305 Boise LH 139 375 Bojarska-Junak A 353 S273
Page 1 and 2:
Focussed Symposia Arsenic trioxide
Page 3 and 4:
assess whether such a program will
Page 5 and 6:
The overall response rate was noted
Page 7 and 8:
Figure 5A Table 1: VEL + THAL for R
Page 9 and 10:
naturally occurring OPG. Present tr
Page 11 and 12:
0.505). Finally, the multiple event
Page 13 and 14:
CLINICOPATHOLOGICAL DEFINITION OF W
Page 15 and 16:
Plenary Sessions 1. Development of
Page 17 and 18:
clonotypic IgH VDJ signature confir
Page 19 and 20:
can be considered as two entities,
Page 21 and 22:
immunofluorescence staining for DKK
Page 23 and 24:
P2.3 DEVELOPMENT OF A MULTIPLE MYEL
Page 25 and 26:
P2.5 MOLECULAR CYTOGENETICS OF MYEL
Page 27 and 28:
clear that the biggest challenge fo
Page 29 and 30:
esponse and have demonstrated that
Page 31 and 32:
variable region of the idiotypic im
Page 33 and 34:
4. From MGUS to symptomatic MM Fig.
Page 35 and 36:
(MRI); some have claimed that level
Page 37 and 38:
P4.5 CYTOKINES IN MGUS: THERAPEUTIC
Page 39 and 40:
preventing phosphorylation of p70S6
Page 41 and 42:
transducing component of the interl
Page 43 and 44:
survive initial drug exposure and a
Page 45 and 46:
quiescent counterpart, the human um
Page 47 and 48:
transcriptional activity of NF-êB;
Page 49 and 50:
manifestations and anomalous protei
Page 51 and 52:
P7.4 ROLE OF SERUM FREE LIGHT CHAIN
Page 53 and 54:
P7.6 IMMUNOPHENOTYPIC INVESTIGATION
Page 55 and 56:
presumably through the circulation,
Page 57 and 58:
9. Chemotherapy, maintenance treatm
Page 59 and 60:
stratified according to their antim
Page 61 and 62:
explore higher doses of zoledronic
Page 63 and 64:
initial therapy. However, the role
Page 65 and 66:
P10.2.2 SINGLE VERSUS TANDEM HIGH D
Page 67 and 68:
With a median follow-up of 38 month
Page 69 and 70:
cells could be harvested following
Page 71 and 72:
11. What is the role of allogeneic
Page 73 and 74:
found that 75% of patients who were
Page 75 and 76:
patients with responsive disease 3
Page 77 and 78:
9. Giralt S, Estey E, Albitar M, et
Page 79 and 80:
Badros A, Barlogie B, Siegel E, et
Page 81 and 82:
Figure 3b. Event-free Survival 4-Ye
Page 83 and 84:
improve patient outcome in MM. Impo
Page 85 and 86:
myeloma and in 40% of previously un
Page 87 and 88:
degrade OPG in the same way as myel
Page 89 and 90:
P12.2.5 MONOCLONAL ANTIBODY THERAPY
Page 91 and 92:
myeloma. Blood 2001; 98:210-216. 6.
Page 93 and 94:
MHC molecules, in effectively prese
Page 95 and 96:
mice demonstrate that class II-spec
Page 97 and 98:
detected in 293 and NIH3T3 cells. S
Page 99 and 100:
hypothesis that (1) CCND1 and FGFR3
Page 101 and 102:
patient samples. In addition, the p
Page 103 and 104:
016 NEUTRAL ENDOPEPTIDASE (CD10) KN
Page 105 and 106:
2. Genetic heterogeneity in MM: imp
Page 107 and 108:
evidence from two t(11;14) cases wh
Page 109 and 110:
immunoglobulin heavy chain (IgH) lo
Page 111 and 112:
034 Instability of Pericentromeric
Page 113 and 114:
clusters were found, the first was
Page 115 and 116:
MGUS but most likely not crucial fo
Page 117 and 118:
Objective: To compare the impact on
Page 119 and 120:
4 patients had MMSET/IgH but did no
Page 121 and 122:
and clonal PC from MGUS, MM and PCL
Page 123 and 124:
059 VEGF receptor expresion in Mult
Page 125 and 126:
two HLA-A2+ myeloma patients with C
Page 127 and 128:
molecules expressed on the surface
Page 129 and 130:
Recognition of these antigens appea
Page 131 and 132:
Diagnosis requires a single area of
Page 133 and 134:
081 Incidence of solid tumors in co
Page 135 and 136:
Growth Factor (VEGF), Hepatocyte Gr
Page 137 and 138:
PC-AI levels of MGUS and SMM patien
Page 139 and 140:
093 The predominant pathway of tran
Page 141 and 142:
was associated with I.V. line, whil
Page 143 and 144:
103 Vascular amyloidosis induces se
Page 145 and 146:
5. Signal transduction pathways and
Page 147 and 148:
integrin in IGF-1-triggered MM cell
Page 149 and 150:
118 IL-6- Induced Phosphorylation o
Page 151 and 152:
123 THE IGF/IGF-1R SYSTEM IS A MAJO
Page 153 and 154:
human myeloma cell line (HMCL) to a
Page 155 and 156:
ligation or dexamethasone (Georgii-
Page 157 and 158:
6. Role of microenvironment 6.1 Cel
Page 159 and 160:
141 Human myeloma cells adhere to f
Page 161 and 162:
145 STUDY OF BONE MARROW ANGIOGENES
Page 163 and 164:
patients, the growth of primary mye
Page 165 and 166:
tibia (con=49.1±0.7mg/cm2 vs 5T2=4
Page 167 and 168:
157 The Nitrogen-Containing Bisphos
Page 169 and 170:
7. New prognostic criteria for clas
Page 171 and 172:
atio of >3. This system has subdivi
Page 173 and 174:
Patient 1 (IgG/κ);IgG - 16.5 days,
Page 175 and 176:
176 Pro-inflammatory and angiogenic
Page 177 and 178:
180 Clinical study on the bone lesi
Page 179 and 180:
7.2 Imaging studies 185 99mTc-MIBI
Page 181 and 182:
189 Factors Predicting Occult Spina
Page 183 and 184:
vivo detected resonances was invest
Page 185 and 186:
Support Unit (CTSU) with flexibilit
Page 187 and 188:
(β2m) & C reactive protein (CRP).
Page 189 and 190:
plasmids carrying the clonotypic in
Page 191 and 192:
newly diagnosed multiple myeloma as
Page 193 and 194:
216 Transgenic expression of Myc an
Page 195 and 196:
221 Prolonged survival in the 5T2MM
Page 197 and 198:
9. Chemotherapy, maintenance, treat
Page 199 and 200:
229 EFFECTIVENESS OF STANDARD CHEMO
Page 201 and 202:
234 Melphalan and Dexamethasone- Is
Page 203 and 204:
Methods. We investigated the VECD p
Page 205 and 206:
9.2 Renal complications. 243 MERIT
Page 207 and 208:
cost of SRE-related care was $10,24
Page 209 and 210:
those with Hb >13 g/dL. Analysis of
Page 211 and 212:
sustained response, lasting from 52
Page 213 and 214:
proportion of bone abnormality. IgD
Page 215 and 216:
disease. The lack of response to in
Page 217 and 218:
yielding a median of 3x106/kg CD34
Page 219 and 220:
patients(pts) aged ≥60 yrs. We co
Page 221 and 222:
PBSC mobilizing regimen utilizing C
Page 223 and 224:
their leukocytes and platelets. No
Page 225 and 226:
25 Gy to marrow. The tracer dose wa
Page 227 and 228:
non-CR after the first transplant a
Page 229 and 230:
296 PERIPHERAL BLOOD STEM CELL TRAN
Page 231 and 232: References Effect of dose-intensive
Page 233 and 234: with cyclosporine A and methotrexat
Page 235 and 236: 11.Role of novel therapies targetin
Page 237 and 238: 312 Thalidomide as Rescue of Relaps
Page 239 and 240: patients, light chain in 1 patients
Page 241 and 242: platelets of 207 (76-402), B2M of 3
Page 243 and 244: 325 Low Dose Thalidomide plus Dexam
Page 245 and 246: in 5 pts (11%), M protein decreased
Page 247 and 248: time from diagnosis was 3.7 years a
Page 249 and 250: 339 Thalidomide, Clarithromycin and
Page 251 and 252: 344 COMBINATION OF THALIDOMIDE, DEX
Page 253 and 254: experienced early death during the
Page 255 and 256: untreated patients with high tumor
Page 257 and 258: 357 Thalidomide protects endothelia
Page 259 and 260: 362 EOSINOPHILIA IS A VERY COMMON F
Page 261 and 262: 11.5 CC 4047, PS 341 and arsenic tr
Page 263 and 264: without chromosome 13. Mean IC50 fo
Page 265 and 266: myeloma patients. Phase I data indi
Page 267 and 268: 11.6 Other drugs 380 EFFECT OF STI5
Page 269 and 270: significant inhibition of cell prol
Page 271 and 272: which acts to prevent the synthesis
Page 273 and 274: of B and its metabolites, however,
Page 275 and 276: and 10 months after start of therap
Page 277 and 278: terminal kinase (JNK) pathway which
Page 279 and 280: lymphocytes was tested by Ellispot.
Page 281: 411 Dendritic Cell-Based Idiotype V
Page 285 and 286: De La Serna J 291 De Laurenzi A P11
Page 287 and 288: Hull DR 338 Hullen C P10.2.1 Humes
Page 289 and 290: Morra E 249 280 359 Morris CM 226 M
Page 291 and 292: Siegel D 70 115 250 Sierra J 304 30
show all

Haematologica 2003 - Supplements

Create successful ePaper yourself

Delete template?

Save as template?